Researcher.Life Logo

Current Cancer Drug Targets : Impact Factor & More

eISSN: 1873-5576pISSN: 1568-0096

Aims and Scope of Current Cancer Drug Targets

Current Cancer Drug Targets is a peer-reviewed medical journal published by Bentham Science Publishers. The editor-in-chief is Ruiwen Zhang (UH Drug Discovery Institute). The journal covers research on contemporary molecular drug targets involved in cancer, including medicinal chemistry, pharmacology, molecular biology, genomics, and biochemistry. Current Cancer Drug Targets publishes original research reports, review papers, and rapid communications ("letters"). Less

Key Metrics

CiteScore
6.4
H-Index
99
Impact Factor
< 5
SJR
Q2Oncology
SNIP
0.85
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Current Cancer Drug Targets

Current Cancer Drug Targets Journal Specifications

Overview
Publisher BENTHAM SCIENCE PUBL LTD
Language English
Frequency Monthly
General Details
LanguageEnglish
FrequencyMonthly
Publication Start Year2000
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Current Cancer Drug Targets ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Current Cancer Drug Targets

Ectophosphatase Activity in Human Hepatocellular Carcinoma Huh7 Cells: Characterisation and Implications for the Tumour Microenvironment
  • 13 May 2026
  • Current Cancer Drug Targets
Research Progress on Immunotherapy Targets in Nasopharyngeal Carcinoma.
  • 9 May 2026
  • Current cancer drug targets
HPGD Inhibited Natural Killer Cell Activation and Enhanced Autophagy to Promote the Progression of Papillary Thyroid Cancer by Activating the JAK2/STAT3 Pathway.
  • 8 May 2026
  • Current cancer drug targets
Impact of ncRNAs on Immunocyte Regulation and Antitumor Immune Responses in Cancer.
  • 8 May 2026
  • Current cancer drug targets
Anlotinib for Advanced Peritoneal Follicular Dendritic Cell Sarcoma: A Case Report and Literature Revie.
  • 4 May 2026
  • Current cancer drug targets
PCK2 Promotes Non-Small Cell Lung Cancer Progression via SLC38A2- Mediated Glutamine Uptake and mTORC1 Activation.
  • 28 Apr 2026
  • Current cancer drug targets
Ectophosphatase Activity in Human Hepatocellular Carcinoma Huh7 Cells: Characterisation and Implications for the Tumour Microenvironment
  • 13 May 2026
  • Current Cancer Drug Targets
Research Progress on Immunotherapy Targets in Nasopharyngeal Carcinoma.
  • 9 May 2026
  • Current cancer drug targets
HPGD Inhibited Natural Killer Cell Activation and Enhanced Autophagy to Promote the Progression of Papillary Thyroid Cancer by Activating the JAK2/STAT3 Pathway.
  • 8 May 2026
  • Current cancer drug targets
Impact of ncRNAs on Immunocyte Regulation and Antitumor Immune Responses in Cancer.
  • 8 May 2026
  • Current cancer drug targets
Anlotinib for Advanced Peritoneal Follicular Dendritic Cell Sarcoma: A Case Report and Literature Revie.
  • 4 May 2026
  • Current cancer drug targets
PCK2 Promotes Non-Small Cell Lung Cancer Progression via SLC38A2- Mediated Glutamine Uptake and mTORC1 Activation.
  • 28 Apr 2026
  • Current cancer drug targets

FAQs on Current Cancer Drug Targets